GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $2.90 $4.87 Friday, 27th Jan 2023 CLBS stock ended at $3.55. This is 1.14% more than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 1.43% from a day low at $3.50 to a day high of $3.55.
90 days $2.90 $4.87
52 weeks $0.402 $9.75

Historical Caladrius Biosciences prices

Date Open High Low Close Volume
2022-04-11 $0.710 $0.721 $0.690 $0.695 128 384
2022-04-08 $0.730 $0.750 $0.690 $0.710 189 400
2022-04-07 $0.710 $0.720 $0.700 $0.720 96 500
2022-04-06 $0.720 $0.730 $0.710 $0.710 107 900
2022-04-05 $0.740 $0.750 $0.720 $0.720 102 100
2022-04-04 $0.730 $0.760 $0.730 $0.740 90 900
2022-04-01 $0.723 $0.753 $0.723 $0.752 144 976
2022-03-31 $0.755 $0.769 $0.721 $0.732 126 456
2022-03-30 $0.770 $0.780 $0.736 $0.760 183 221
2022-03-29 $0.740 $0.780 $0.740 $0.760 232 100
2022-03-28 $0.750 $0.770 $0.710 $0.740 166 400
2022-03-25 $0.790 $0.790 $0.750 $0.760 304 300
2022-03-24 $0.710 $0.80 $0.710 $0.780 600 300
2022-03-23 $0.750 $0.750 $0.710 $0.730 285 700
2022-03-22 $0.750 $0.750 $0.710 $0.740 313 558
2022-03-21 $0.738 $0.754 $0.718 $0.748 224 832
2022-03-18 $0.680 $0.759 $0.680 $0.737 669 763
2022-03-17 $0.650 $0.690 $0.650 $0.680 478 200
2022-03-16 $0.640 $0.680 $0.630 $0.660 221 400
2022-03-15 $0.670 $0.680 $0.630 $0.630 249 400
2022-03-14 $0.700 $0.710 $0.630 $0.650 412 300
2022-03-11 $0.730 $0.730 $0.680 $0.680 301 300
2022-03-10 $0.700 $0.710 $0.680 $0.710 226 600
2022-03-09 $0.700 $0.710 $0.690 $0.700 335 100
2022-03-08 $0.680 $0.700 $0.680 $0.690 146 500
Click to get the best stock tips daily for free!

About Caladrius Biosciences

Caladrius Biosciences Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysf... CLBS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT